Cargando…
Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
INTRODUCTION: While it is recommended that patients with multiple sclerosis (MS) be vaccinated against COVID-19, it is unknown what the vaccine response is in MS patients treated with fingolimod, an agent which modulates the humoral response. We aimed to characterize the immune response to the COVID...
Autores principales: | Ciccone, A., Mathey, G., Prunis, C., Debouverie, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727589/ https://www.ncbi.nlm.nih.gov/pubmed/36496270 http://dx.doi.org/10.1016/j.neurol.2022.11.003 |
Ejemplares similares
-
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021) -
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Barzegar, Mahdi, et al.
Publicado: (2020) -
Disseminated Histoplasmosis in a Patient With Multiple Sclerosis
Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021) -
Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023) -
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
por: Foerch, Christian, et al.
Publicado: (2020)